Technology evaluation: Denosumab, Amgen

Bo Abrahamsen, Andy Y.T. Teng

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

    Abstrakt

    Amgen, as part of it's program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-κ B ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.

    OriginalsprogEngelsk
    Sider (fra-til)604-610
    Antal sider7
    TidsskriftCurrent Opinion in Molecular Therapeutics
    Vol/bind7
    Udgave nummer6
    StatusUdgivet - 1 dec. 2005

    Fingeraftryk Udforsk hvilke forskningsemner 'Technology evaluation: Denosumab, Amgen' indeholder.

    Citationsformater